Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Gastroesophageal Junction Adenocarcinoma
- Stomach Neoplasms
Interventions
- COMBINATION_PRODUCT: Avelumab addition to perioperative chemotherapy in GC and GEJC
Sponsor
Vall d'Hebron Institute of Oncology